Press Releases
April 26, 2002
Neurotech announces Senior Management changes
Paris, April 26, 2002 Neurotech S.A., specialist in the discovery,
development and commercialization of retinal and other eye therapies,
announces today the appointment of Bernard Chauvin, former President
and Chief Executive Officer of Groupe Chauvin, a leading ophthalmic
company, as Chairman of the Board and interim Chief Executive Officer.
Furthermore, Neurotech SA announces the promotion of Bernard Davitian,
former Chief Financial Officer, as Executive Vice President and
Chief Operating Officer. These decisions result from the resignation
of Tom Shepherd, who has decided to go back to Scotland for family
reasons.
Commenting on his appointment, Bernard Chauvin said: "I am
very pleased to join Neurotech, which represents for me, after 20
years of experience in ophthalmology, one of the most exciting innovative
companies in the field".
Tom Shepherd said: "I am very sad to be leaving Neurotech
at this time for personal reasons. I am very glad however that we
have in the organization Bernard Chauvin and Bernard Davitian who
can take over my responsibilities and ensure strong management continuity".
About Neurotech:
Neurotech S.A. is a French based biotechnology company developing
cell therapy and protein delivery products in the eye. Neurotech's
Encapsulated Cell Technology (ECT) allows, for the first time, the
long term administration of protein drugs in the eye and CNS. In
addition to the ECT, Neurotech has a portfolio of cell therapy products
in development to treat eye and CNS disease. Neurotech has R&D
operations in France and the United States and is supported by an
international group of investors including: Merlin Biosciences,
Apax Partners, 3i Plc, Atlas Venture, Westdeutsche Landesbank Girozentrale,
GIMV, CDC-Innovation, Sofinnova, ABN Amro, AGF Innovation, Rothschild,
Banexi, IMH, Private Equity Holdings, Sudinnova, and Banque de Vizille.
For more information on Neurotech: www.neurotech.fr
For further information please contact :
Ted Danse, CEO
Neurotech
Phone: 1 401 333-3880 x3116
Email: t.danse@neurotechusa.com
|
